Age: 82.0
Sex: M
Vaccine: COVID19
Symptoms: Pruritus, Rash erythematous
Clinical narrative: Generalised Itching; Red rash with pain; Red rash with pain; diagnosed with shingles; Irregular heart rate/Palpitations; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Generalised Itching), PAIN (Red rash with pain), RASH ERYTHEMATOUS (Red rash with pain), HERPES ZOSTER (diagnosed with shingles) and PALPITATIONS (Irregular heart rate/Palpitations) in an 82-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 025J20A and 013L20A) for COVID-19 vaccination.     Previously administered products included for Shingles: Shingles vaccine (1st dose on 21-Oct-2019 and the 2nd dose on 14-Jul-2020.) from 21-Oct-2019 to 14-Jul-2020; for an unreported indication: VITAMIN B-12 (Injection on left arm.) since 01-Apr-2021. Concurrent medical conditions included Atrial fibrillation since 03-Dec-2019. Concomitant products included METOPROLOL from 01-Jul-2019 to an unknown date and LOSARTAN from 27-Dec-2019 to an unknown date for Blood pressure management, LOVASTATIN from 20-Mar-2008 to an unknown date for Cholesterol, APIXABAN (ELIQUIS) from 14-Jan-2019 to an unknown date for Heart disorder, ASCORBIC ACID, CUPRIC OXIDE, DL-ALPHA TOCOPHERYL ACETATE, XANTOFYL, ZEAXANTHIN, ZINC OXIDE (PRESERVISION AREDS 2) and CYANOCOBALAMIN (VITAMIN B-12) for an unknown indication.   On 27-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 28-Apr-2021, the patient experienced PRURITUS (Generalised Itching), PAIN (Red rash with pain), RASH ERYTHEMATOUS (Red rash with pain), HERPES ZOSTER (diagnosed with shingles) and PALPITATIONS (Irregular heart rate/Palpitations). The patient was treated with GABAPENTIN on 23-Jun-2021 for Adverse event, at a dose of 300 milligram; LIDOCAINE, PRILOCAINE (LIDOCAINE/PRILOCAINE) (topical) ongoing from 16-Jun-2021 for Adverse event, at an unspecified dose and frequency; PREGABALIN (oral) ongoing from 23-Jun-2021 for Adverse event, at a dose of 100 milligram three times a day and CODEINE PHOSPHATE, PARACETAMOL (ACETAMINOPHEN AND CODEINE) for Adverse event, at a dose of Every 6 hours. On 12-May-2021, RASH ERYTHEMATOUS (Red rash with pain) had resolved. At the time of the report, PRURITUS (Generalised Itching), PAIN (Red rash with pain) and PALPITATIONS (Irregular heart rate/Palpitations) had not resolved and HERPES ZOSTER (diagnosed with shingles) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Apr-2021, Blood pressure measurement: 121/78 (abnormal) 120/78 mmhg. On 28-Apr-2021, Heart rate: 57 (Low) 57 beats per minute.         Most recent FOLLOW-UP information incorporated above includes: On 27-Jul-2021: Added Demographic details, Lab tests data. Concomitant medications and start dates were added. New events for second dose and outcome of the events were updated. On 28-Jul-2021: Follow up received and contain No new information. On 29-Jul-2021: Follow up received and contain No new information.